Health Rounds: Amgen blood platelet booster helps patients who need chemotherapy

Amgen's Nplate demonstrated significant efficacy in preventing chemotherapy-induced thrombocytopenia in cancer patients, with 84% of patients on Nplate avoiding chemotherapy dose reductions compared to 36% in the placebo group, according to a study presented ahead of the American Society of Clinical Oncology meeting. The trial, involving patients with colorectal, gastroesophageal, or pancreatic cancer, showed that Nplate recipients were over 10 times more likely to continue cancer treatments without dose reduction, addressing a critical unmet need as there are currently no FDA-approved drugs for this condition. Separately, research indicates that AI can improve the accuracy of HER2 level assessments in breast cancer patients, potentially expanding access to targeted therapies like AstraZeneca’s Enhertu, while a trial involving BeiGene's Tevimbra suggests that adding it to pre-operative chemotherapy for esophageal cancer may improve outcomes, though further studies are needed.

Analysis

Amgen's (AMGN.O) Nplate has demonstrated significant clinical utility beyond its current autoimmune indication, with pivotal trial data revealing high efficacy in preventing chemotherapy-induced thrombocytopenia (CIT) in cancer patients. Researchers reported that 84% of patients receiving Nplate for CIT avoided chemotherapy dose reductions, compared to only 36% in the placebo group, indicating a substantial improvement in maintaining treatment intensity. Patients on Nplate were over ten times more likely to continue their cancer treatments without dose reduction, a critical factor given that reduced chemotherapy intensity is linked to worsened survival outcomes. This development is particularly noteworthy as there are currently no FDA-approved drugs for CIT, positioning Nplate for a potentially practice-changing role in oncology supportive care. Separately, advancements in artificial intelligence, funded by AstraZeneca (AZN.L), show promise in enhancing diagnostic accuracy for HER2 protein levels in breast cancer. Pathologists' accuracy in determining HER2 clinical categories improved from 66.7% to 88.5% with AI assistance, significantly reducing misclassification of HER2-ultralow cases from 29.5% to 4.0%. This could expand the eligible patient pool for HER2-targeted therapies like AstraZeneca's Enhertu. Additionally, BeiGene's (688235.SS) Tevimbra, an immunotherapy drug, showed positive results in a mid-stage trial for operable esophageal cancer when added pre-operatively after standard chemotherapy. Tevimbra-treated patients had a pathological complete response rate of 40.7% versus 18.1% in the control group. While one-year progression-free survival was higher at 95.6% compared to 77.3%, this difference was not statistically significant, necessitating larger trials to confirm these promising trends.

Key Decisions for Investors

• Investors should consider the potential market expansion for Amgen's Nplate into oncology supportive care, given the strong trial data for chemotherapy-induced thrombocytopenia and the current lack of FDA-approved alternatives.
• The AI-driven improvement in HER2 testing accuracy may positively impact AstraZeneca's Enhertu, by potentially increasing the identifiable patient population for its targeted therapy; monitor adoption rates of such AI diagnostic tools.
• For BeiGene, the Tevimbra data in operable esophageal cancer is encouraging but early; investors should await results from larger, late-stage trials, particularly focusing on statistically significant progression-free survival data, before factoring in a major shift in standard-of-care.
• Monitor further presentations and data releases from the American Society of Clinical Oncology meeting, as these often serve as significant catalysts for companies in the oncology space.